Clinical trial
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed…
NCT00005601 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00005601 |
|---|---|
| Title | Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma |
| Official title | A Phase II Trial of Cisplatinum, Cytosine Arabinoside, Dexamethasone (DHAP) With Rituxan in Patients With Relapsed CD20+ B-Cell Non-Hodgkin's Lymphoma |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | rituximab, cisplatin, cytarabine, dexamethasone, sargramostim |
| Enrollment | 58 |
| Start date | Oct 1, 2000 |
| Primary completion | Jul 1, 2003 |
| Completion | Feb 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 7, 2016 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: